Reliable diagnosis of respiratory infection due to Chlamydia pneumoniae and investigation of its role in chronic diseases remain difficult because of the absence of well-standardized and commercially available diagnostic tests. In 2001, the US Centers for Disease Control and Prevention published recommendations for standardizing the diagnostic approach. In this review, we discuss the current state of knowledge of C. pneumoniae-associated respiratory infections in the context of epidemiological studies published during the past 5 years, with particular emphasis on the diagnostic strategies used and their impact on results. The single most likely factor underlying wide variations in data is the significant interstudy variation of the choice of diagnostic methods and criteria used. Adoption of a more unified approach, both for choices of diagnostic methods and for validation of new molecular assays, is long overdue and will be critically important for development of a standardized test for clinical laboratories.
testing in 2001 [1] . We reviewed the epidemiology of C. pneumoniae-associated respiratory infections in studies performed all over the world for the purpose of examining the current state of knowledge of C. pneumoniae diagnostics since the publication of the above-mentioned guidelines.
EPIDEMIOLOGY OF RESPIRATORY INFECTION DUE TO C. PNEUMONIAE
Studies of C. pneumoniae infection published during the 1990s found the organism to be associated with 6%-22% of lower respiratory tract infections in children and adults, varying with the population studied and diagnostic methods used [2] . Thirty additional studies have been published about C. pneumoniaeassociated lower respiratory infections since 2000. Data from selected studies chosen to represent different populations from around the world are summarized in tables 1 [3] [4] [5] [6] [7] [8] [9] and 2 [10] [11] [12] [13] [14] [15] [16] . As shown in these tables, the proportion of lower respiratory tract infections in children and adults, including community-acquired pneumonia, associated with C. pneumoniae infection during the past 5 years has ranged from 0% to 44.2%, varying with age and the geographic location of the population examined and the diagnostic methods used [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . The diagnosis of C. pneumoniae infection in most studies was based on serological testing alone [6, 12, 13, 16] ; some used a PCR assay alone [15] or a serological test and a PCR assay [3, 4, 7, 10, 11, 14] , and only 2 studies used culture in combination with a serological test or PCR assay [8, 11] . Despite the CDC recommendations [1] , there was a high degree of heterogeneity from study to study in the serological methods and criteria used. In a number of studies, the type of assay and the criteria used were not specified, thereby making it difficult, if not impossible, to compare results from one study to another. One example is a prospective study of the incidence and etiology of lower respiratory tract illness in outpatient adults in the United Kingdom [3] , published in 2001. The researchers used serological methods and "a gene amplification assay" for the diagnosis of C. pneumoniae infection. Seventeen percent of the patients were thought to have serological evidence of C. pneumoniae infection, but no information was provided on the serological method used. Also, no specific information was given for the "gene amplification" assay, although no patients had positive results by that method. Furthermore, the study had no control subjects, and because of their absence, the significance of the reported seroprevalence of the patient group cannot be known. Background rates of seropositivity can be very high in some adult populations, often exceeding 80% [2] .
More recent studies using PCR assays have, in general, reported lower rates of C. pneumoniae-associated lower respiratory tract illnesses than have been found in studies using serological testing [7, 9, 15] . A multicenter prospective study investigating the incidence of C. pneumoniae infection in adult ambulatory ( ) and hospitalized ( ) patients n p 182 n p 364 with community-acquired pneumonia enrolled in the German Community Acquired Pneumonia Competence Network (CAPNETZ) project used microimmunofluorescence (MIF) testing, as well as 3 previously published PCR assays, to determine single IgM, IgG, or IgA titers [9] . Significant variation in PCR results was reported among the 3 laboratories, each independently experienced in the use of PCR assays. Using PCR positivity in at least 2 of the 3 laboratories to define acute infections, the researchers identified C. pneumoniae infection in 5 (0.9%) of 546 case patients. Of these 5 case patients, MIF tests were performed for 3 patients, and all results were negative for anti-C. pneumoniae IgG, IgM, or IgA antibodies. These data confirmed the lack of correlation of serological methods with culture and/or PCR assays reported in earlier studies [2] . One explanation for the recently reported low prevalence of C. pneumoniae infection by several investigators could be that C. pneumoniae infections in populations may be cyclical in nature and that the current study may reflect a nadir of its epidemic or endemic cycle. We previously observed a similar epidemiological trend for the association of C. pneumoniae with respiratory illness in children and adults in Brooklyn, New York [17] .
The epidemiological data emerging from pediatric studies have revealed similar inconsistencies of the methods and criteria used to make a diagnosis of acute C. pneumoniae infection. Examples include the use of single IgG titers by the vast majority of studies [10] [11] [12] , despite the fact that the CDC guidelines discouraged their use, particularly for children; the use of IgA titers, which have not been recommended and yet frequently are used to define acute and chronic infections [11, 13] ; and the use of titer cutoffs that deviate significantly from the proposed criteria [6, 16] .
Two small, uncontrolled pediatric studies in Dallas, Texas [13] , and Greece [14] , conducted in 2004, identified C. pneumoniae infection in 9% and 3% of patients with pneumonia, respectively; both centers used MIF and EIA for serological testing, and the study from Greece used a nested PCR assay. Both centers correctly used 4-fold increases of IgG or single IgM titers of у1:16 as evidence of acute infection. However, Michelow et al. [13] , who additionally included 4-fold increases of IgA antibody levels (not recommended) for their diagnostic panel, did not specify the proportion of positive results by the different antibody classes, and neither center stated the proportion of positive results from the use of MIF testing and EIA. Despite the limitations associated with the use of MIF testing, particularly for children (see below), most pediatric studies continue to rely on serological methods alone. Given the wide variations of data about C. pneumoniae-associated respiratory infections from studies with equally wide variation of and lack of standardized diagnostic methods, discerning the true disease burden due to this pathogen remains a challenge.
SEROLOGICAL METHODS
The most common method still used by investigators for the diagnosis of C. pneumoniae infection is serological testing. Assays available for detection of C. pneumoniae-specific antibodies include MIF tests, ELISAs, and EIAs, each of which exists in a variety of in-house and commercial versions. MIF is considered by the CDC to be the only currently acceptable serological test, and therefore, it is considered to be the reference standard for serodiagnosis, despite the significant limitations [1] . The recommendations proposed by the CDC [1] and restated in the practice guidelines of the Infectious Disease Society of America [18] defined the criteria for the diagnosis of acute C. pneumoniae infection as a single IgM titer of у1:16 or a 4-fold increase in the IgG titer, as determined by MIF testing. The use of single IgG titers was discouraged. However, not only is the literature replete with studies that deviate widely from the proposed guidelines (tables 1 and 2), there are several limitations inherent for serodiagnosis of C. pneumoniae infection, even when these guidelines are observed.
Serological testing, especially if accurate diagnosis requires paired serum samples, at best offers a retrospective diagnosis. The kinetics of the C. pneumoniae antibody response and the time course of symptoms should be taken into consideration for optimal interpretation of serodiagnostic results for any given patient. In primary infections, IgM antibodies appear 2-3 weeks and IgG antibodies appear 6-8 weeks after infection, whereas The MIF assay has been repeatedly and conclusively demonstrated to be insensitive and have poor correlation with the detection of the organism by culture or PCR assay, particularly for children. Seventy percent of children aged 6 months to 16 years in 2 multicenter pneumonia treatment studies and 7 (58.3%) of 12 children aged 5-16 years with acute wheezing and who had culture-documented infection had seronegative results revealed by a MIF test [2] . Only 1%-3% of culturepositive children in the former study and 25% in the latter met the serological criteria for acute infection. The majority of the children had seronegative results, even after 3 months of followup. More recently, Wellinghausen et al. [9] , during the CAP-NETZ study, reported that 17 patients who had positive results by PCR assay and who had community-acquired pneumonia, had seronegative results revealed by a MIF test [9] . The specificity may be suboptimal as well; serological evidence of acute infection (MIF IgM titer of у1:16 or IgG titer of у1:512) was found in 19% of subjectively healthy adults who had negative results by culture and PCR [2] . This lack of specificity may have resulted from serological cross-reactivity with other chlamydial species, as well as Mycoplasma, Bartonella, and Yersinia species.
In addition, drawbacks of the MIF test include lack of standardization of reagents, technical complexity, and subjective end points, all of which result in significant intra-and interlaboratory variation of test performance. A recent study evaluated the interlaboratory reliability of the MIF test for measurement of C. pneumoniae-specific IgA and IgG titers for 392 serum samples, using reagents and antigens obtained from a common source. The investigators reported the exact agreement of IgA and IgG titers to be 55% and 38%, respectively, and the agreement within a 2-fold dilution to be 75% and 66%, respectively [19] . EIAs may overcome some of the limitations of the MIF test by being objective and less technically complex. However, the CDC did not endorse any EIA pending demonstration of adequate sensitivity and specificity compared with the MIF test. Hermann et al. [20] compared 7 commercial EIAs or ELISAs (1 of which was genus-specific) with 4 MIF assays for detection of specific IgG antibodies, using serum samples from 80 healthy subjects, and reported sensitivities and specificities ranging from 88% to 100% and from 42% to 100%, respectively. Hoymans et al. [21] compared 5 commercially available serological assays (3 species-specific EIAs and ELISAs, 1 genus-specific recombinant ELISA, and 1 MIF test) for detection of specific IgG in serum samples obtained from 112 healthy subjects and 106 patients with coronary atherosclerosis.
The range of sensitivities and specificities was 62%-97% and 71%-87%, respectively, compared with the MIF test. Most important, Hoymans et al. [21] demonstrated that a significant difference in the seroprevalence between patients and control subjects found with 1 of the EIAs was not confirmed by MIF testing, therefore illustrating the impact of assay choice on epidemiological studies of the association of C. pneumoniae with various diseases [21] . Finally, although persistently elevated IgA (or IgG) antibody levels have been proposed and used by some researchers to indicate chronic infection, there is no validated serological marker of persistent infection [1] .
PCR
At the time of the 2001 CDC recommendations, there were 18 published in-house PCR assays for detection of C. pneumoniae DNA [1] , 4 of which were thought by the CDC to be adequately validated. However, validation was primarily analytical; none of these assays was extensively evaluated using clinical specimens. Since then, an additional 13 assays have been described [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] (table 3) . However, we still do not have a commercially available, standardized assay approved by the US Food and Drug Administration for detection of C. pneumoniae in respiratory or other specimens. None of the currently existing assays have been extensively validated against cultures of a wide variety of clinical specimens obtained from a wide geographic area. Despite an increasing body of literature describing the use of these assays for detection of C. pneumoniae in various diseases, no definite conclusions can be drawn on their performance in a clinical context. This deficiency is because of the great variation of the methods used from study to study, including variability of target (16S rRNA, ompA, PstI, PmP4, and cytadhesin gene; monoplex versus multiplex targets) and of nucleic acid amplification (conventional, nested, and real-time; RNA vs. DNA targets; and PCR and nucleic acid sequence-based amplification technologies) and detection (agarose gel electrophoresis, SYBR green, TaqMan probe, hybridization probes, molecular beacons, and microchip electrophoresis) formats. Many factors can affect the performance of in-house assays [34] . Interstudy variation is further compounded by the use of different specimens obtained for detection of C. pneumoniae in the absence of a widely accepted optimal specimen source (sputum, nasopharyngeal, or oropharyngeal swabs or washes; bronchoalveolar lavage; or pleural fluid) and even the reference diagnostic assay with which the new assay is compared (a serological test, culture, or a preexisting PCR assay). Each of the latter is again susceptible to the same inconsistencies-for example, the use of different serological assays and titer cutoffs that vary significantly from the proposed consensus guidelines. Finally, none of the tests available has been standardized, and this leads to a significant interlaboratory variation of performance. This lack of conformity of different studies renders it very difficult to compare the data from study to study.
Multicenter studies that use a large and geographically diverse repertoire of clinical specimens and compare data from 12 centers independently are likely to provide important insights into the performance of new assays. To date, only 2 such studies describing multicenter comparisons of the performance of various nucleic acid amplification tests for detection of C. pneumoniae in respiratory specimens have been published, and both studies revealed significant variations of test performance from laboratory to laboratory. Chernesky et al. [35] compared an industry-derived C. pneumoniae PCR research kit (LCx assay; Abbott) with 5 conventional PCR assays, using specimens spiked with preextracted DNA. Loens et al. [36] used spiked respiratory specimens to compare the performance of several in-house PCR assays being used by 15 laboratories in Belgium, each with their own extraction and amplification protocols. Both of these studies, as well as 2 multicenter studies comparing the performance of nucleic acid amplification tests for detection of C. pneumoniae in atheroma specimens [37, 38] , revealed significant intercenter discordance of detection rates, using different or even the same tests, despite the fact that the laboratories participating were very experienced with the use of PCR assays. Of importance, the latter 2 studies revealed that nested PCR assays have significant problems with contamination that may be impossible to avoid, which resulted in the overestimation of disease attributed to C. pneumoniae [37, 38] .
It has been proposed that industry-produced assays in kit form may enable standardization. The LCx assay, the only such kit available, was reported to have 100% sensitivity (when the sample contained 11 copy of C. pneumoniae DNA per mL) and specificity, superior to that of the comparators, for detection of C. pneumoniae in preextracted, purified DNA [35] . However, the sensitivity of all assays, including the LCx assay, was dependent on DNA copy number, and further evaluations using clinical specimens that may have a low load of the organism are needed. Real-time assays, although described to have distinct advantages over conventional assays [34] , await similar validation and standardization.
CULTURE
Culture has traditionally been considered to be the referencestandard diagnostic method. The CDC guidelines recommended validation of new PCR assays by comparison with culture and at least 1 other validated PCR assay with a different genetic target. However, in view of the limitations of chlamydial culture-mainly its technical complexity, limited availability, and variable yield-performance of culture remains limited to relatively few laboratories worldwide. Although culture is and will remain essential for further biological and molecular characterization of clinical isolates, its use as a routine diagnostic tool is suboptimal. Perhaps it is time to collectively direct our efforts toward developing new reference standards, the most likely candidates being RT-PCR assays. Collaborative, largescale, multicenter, prospective studies will facilitate optimal validation of new emerging PCR assays by enabling collection of a diverse pool of clinical specimens as well as evaluation by concurrent performance of cultures.
CONCLUSIONS AND FUTURE DIRECTIONS
Significant limitations continue to surround the accurate and reliable diagnosis of C. pneumoniae infection. These include the lack of existence of well-standardized, adequately validated, and commercially available diagnostic tests and the wide variation of the methods and diagnostic criteria used across studies, which results in the subsequent emergence of data that remain incomparable and often controversial because of discordant and, at times, incorrect methodologies used.
It is critically important for current and future investigators to recognize the urgent need for the adoption of a more unified and consistent diagnostic approach. This will, in turn, be made possible by adherence to a common set of recommendations, as were proposed by an international panel of experts in the field in 2001 [1] and restated in the guidelines proposed by the Infectious Diseases Society of America in 2003 [18] . Prospective, well-controlled, blinded, multicenter studies that evaluate fresh clinical specimens obtained from a variety of respiratory sites from populations originating in a large geographic region and use diagnostic approaches in accordance with the CDC guidelines will be critical for providing reliable data and standardization and validation of new tests, particularly PCR assays. Until we have standardized methods, the true role of C. pneumoniae as a respiratory pathogen and its role in chronic diseases will be difficult to ascertain.
